Letter to the Editors-in-ChiefApixaban and rivaroxaban in patients with cerebral venous thrombosis
Section snippets
Conflict of interest statement
The authors declare that they have no conflict of interest.
Funding
Department of Hematology and Oncology at Cleveland Clinic.
Author contributions
FC, HD contributed conception and design of study; FC, TK, OP, and MF collected the data; FC wrote the first draft of the manuscript. All authors contributed to manuscript revision and approved the submitted version.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5).
References (13)
- et al.
Cerebral venous thrombosis: an update
Lancet Neurol.
(2007) - et al.
Apixaban for the treatment of cerebral venous thrombosis: a case series
J. Neurol. Sci.
(2017) - et al.
Cerebral venous sinus thrombosis incidence is higher than previously thought: a retrospective population-based study
Stroke
(2016) - et al.
Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association
Stroke
(2011) - et al.
Oral rivaroxaban for symptomatic venous thromboembolism
N. Engl. J. Med.
(2010) - et al.
Oral apixaban for the treatment of acute venous thromboembolism
N. Engl. J. Med.
(2013)
Cited by (27)
Recanalization and outcomes after cerebral venous thrombosis: a systematic review and meta-analysis
2023, Research and Practice in Thrombosis and HaemostasisTreatment of unusual thrombotic manifestations
2020, BloodCitation Excerpt :Because the phase 3 RCTs conducted on direct oral anticoagulants (DOACs) did not include patients with unusual thrombotic manifestations,76 their safety and efficacy in this setting needs to be proven in dedicated clinical trials, and at present, their use should be discouraged. Limited data are available from 7 case series77-83 reporting on 44 patients with CVST treated with DOACs for a period varying from 3 to 19 months, with complete or partial recanalization achieved in ∼80% of cases without bleeding complications. Table 1 lists the ongoing clinical trials on treatment of CVST with DOACs.
Dabigatran etexilate versus warfarin in cerebral venous thrombosis in Chinese patients (CHOICE-CVT): An open-label, randomized controlled trial
2024, International Journal of StrokeLong-term Anticoagulation with Apixaban in Patients with Cerebral Venous Thrombosis
2023, Clinical and Applied Thrombosis/HemostasisTreatment of Acute Renal Vein Thrombosis With Direct Oral Anticoagulants: A Case Series
2023, American Journal of Therapeutics